Global

‡ In these countries please contact our distributor

Acticoat* In-Vitro Data

This information is intended for Healthcare Professionals only.

 
 
 
 

Sustained Silver Release


Sustained release of nanocrystalline silver provides an antimicrobial barrier, reducing risk of colonisation and preventing infection

 

 

   

Controlled Release of Silver

 
Silver Released (mg/1)
80.03
40.00
0
Controlled Release of Silver graph Silver concentration of Acticoat
 
MIC for Pseudomonoes aeruginosa
 
   
Time (h) 24 48 72
 
    Row rate-0.33ml/h of water through 64cm 2 of Acticoat  

 


Kills Bacteria

Kills bacteria in vitro in as little as 30 minutes, 2-5 times faster than other forms of silver

 

   

MRSA SURVIVAL CURVES

Survivors

Log 10 CFU/ml

 
 
 
 
 
MRSA survival curve TIME (h)

 

KEY:

  Acticoat Dressing   Silver Nitrate  

 

 

 


 

 

 

< Back to Evidence

< Back to Product Page 

 

Nanocrystalline Silver is a patented technology of NUCRYST Pharmaceuticals Corp.
TM SILCRYST is a trademark of NUCRYST Pharmaceuticals Corp, used under licence

All Trademarks are acknowledged